SANTA MONICA, Calif. , May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will

SANTA MONICA, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022 , and provided a

SANTA MONICA, Calif. , May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022 , after the

SANTA MONICA, Calif. , April 29, 2022 /PRNewswire/ --  Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022 , that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC.  Opiant had no knowledge of the press release

Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioid OPNT003 met the primary endpoint of non-inferiority, which was designed to assess whether nasal nalmefene performed as well or better

SANTA MONICA, Calif. , March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021

SANTA MONICA, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr.

SANTA MONICA, Calif. , March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates

SANTA MONICA, Calif. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose.

SANTA MONICA, Calif. , Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support